Catalog5 refs
Tesofensine
MetabolicMetabolic & Weight LosstherapeuticResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine. Originally developed by NeuroSearch for Parkinson's disease and Alzheimer's disease, it was repurposed for obesity after clinical trial participants experienced significant weight loss. While not technically a peptide, tesofensine is widely discussed in peptide research communities for its potent appetite-suppressing and metabolic effects.
Primary Uses
Weight loss
Appetite reduction
appetite suppression
thermogenesis
energy expenditure enhancement
obesity treatment
Obesity pharmacology
Monoamine reuptake inhibition
Appetite suppression studies
Weight-loss trials
Protocol Reference
Dose
0.25–0.5 mg once daily
Frequency
Once Daily, Morning Preferred
Half-life
Long; often cited around 9 days for active moieties
Route
Oral
Evidence
Phase 2 / Phase 2 clinical trials (disputed)
Research References· 2
Research Models
Human
Also in Metabolic